Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: A crossover study

Internal Medicine

Volumn 49, Issue 12, 2010, Pages 1085-1087

  Aoki, Kazutaka ^a   Muraoka, Tomonori ^a   Ito, Yuzuru ^a   Togashi, Yu ^a   Terauchi, Yasuo ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

glucosidase inhibitor; Acarbose; Gastrointestinal adverse effect; Miglitol

Indexed keywords

ACARBOSE; MIGLITOL;

ABDOMINAL PAIN; ABNORMAL FECES COMPOSITION; ADVERSE OUTCOME; ARTICLE; BLOATING; BORBORYGMI; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DRUG WITHDRAWAL; FECES ANALYSIS; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; INCIDENCE; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

1-DEOXYNOJIRIMYCIN; ACARBOSE; ADULT; CROSS-OVER STUDIES; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; MALE;

EID: 77954012600     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3218     Document Type: Article

References (13)

1. Macfarlane DP, Paterson KR, Fisher M. Oral antidiabetic agents as cardiovascular drugs. Diabetes Obes Metab 9: 23-30, 2007.
2. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 166: 1836-1841, 2006.
3. Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther 27: 1064-1073, 2005.
4. Aoki K, Nakamura A, Ito S, et al. Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients. Diabetes Res Clin Pract 78: 30-33, 2007.
5. Aoki K, Nakajima S, Nezu U, Shinoda K, Terauchi Y. Comparison of prevs. postmeal administration of miglitol for 3 months in type 2 diabetic patients. Diabetes Obes Metab 10: 970-972, 2008.
6. Aoki K, Ito Y, Saito K, et al. Comparison of preversus post-meal administration of voglibose in men with or without impaired glucose tolerance. Diabetes Res Clin Pract 83: e31-e32, 2009.
7. Aoki K, Kato H, Terauchi Y. Divided-dose administration of miglitol just before and 15 minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men. Endocr J 54: 1009-1014, 2007.
8. Kageyama S, Nakamichi N, Sekino H, Nakano S. Comparison of the effects of acarbose and voglibose in healthy subjects. Clin Ther 19: 720-729, 1997.
9. Fujisawa T, Ikegami H, Inoue K, Kawabata Y, Ogihara T. Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms. Metabolism 54: 387-390, 2005.
10. Kawamori R, Toyota R, Oka Y, et al. Improvement of glycemic control following 12-week treatment with miglitol in Japanese type 2 diabetes: a double-blind, randomized, placebo and voglibose-controlled trial (Abstract). Diabetes Metab 29: (Horssrie 2) 4S263, 2003.
11. Scott LJ, Spencer CM. Miglitol. A review of its therapeutic potential in type 2 diabetes mellitus. Drugs 59: 521-549, 2000.
12. Samulitis BK, Goda T, Lee SM, Koldovský O. Inhibitory mechanism of acarbose and 1-deoxynojirimycin derivatives on carbohydrases in rat small intestine. Drugs Exp Clin Res 13: 517-524, 1987.
13. Goto Y. Clinical efficacy of miglitol in type 2 Japanese diabetics with diet alone. Jpn Pharmacol Ther 33: 1099-1111, 2005 (In Japanese, Abstract in English).